Application of chemosensitivity test in regional chemotherapy for hepatocellular carcinoma via hepatic artery and portal vein

Nie Lei; Wu DongDe; Zhang Feng; Xia XiaoQin

doi:10.3969/j.issn.1001-5256.2013.08.016

Issue 8

Aug. 2013

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2013 > 29(8): 616-619

PDF( 667 KB)

Application of chemosensitivity test in regional chemotherapy for hepatocellular carcinoma via hepatic artery and portal vein

DOI: 10.3969/j.issn.1001-5256.2013.08.016

Received Date: 2012-10-17
Published Date: 2013-08-20

Abstract

Abstract

Objective To evaluate the chemosensitivities of hepatocellular carcinoma (HCC) to different chemotherapy drugs by 3- (4, 5-dimethylthiazol-2-yl) -2, 5-diphenyl-2H tetrazolium bromide (MTT) assay and to provide guidance for individualized chemotherapy regimen in regional chemotherapy via the hepatic artery and portal vein.Methods Forty-two HCC samples were selected.Primary culture of HCC cells combined with MTT assay were used to evaluate the chemosensitivities of HCC to 5-fluorouracil (5-FU) , cisplatin (DDP) , mitomycin C (MMC) , adriamycin (ADM) , hydroxycamptothecine (HCPT) , gemcitabine (Gemzar) , and oxaliplatin (OXA) .Individualized chemotherapy regimens were developed according to the chemosensitivity test results to guide regional chemotherapy via the hepatic artery and portal vein in 24 of these patients (as an individualized chemotherapy group) .The therapeutic efficacy was compared with that of transcatheter arterial infusion performed in 20 patients (as a control group) .The chi-square test was used for comparison of sensitivity rate, and the rank-sum test was used for comparison of time to progression (TTP) .Results The sensitivity rates of HCC were 64.3% to OXA, 45.2% to HCPT, 40.5% to DDP, 38.1% to Gemzar, 33.3% to ADM, 21.4% to 5-FU, and 16.7% to MMC.Compared with the control group, the individualized chemotherapy group had a significantly higher objective response rate (50.0% vs 20.0%, P= 0.039) , a significantly higher disease control rate (70.8% vs 35.0%, P = 0.017) , and a significantly longer TTP ( (4.7±2.9) m vs (2.6±1.3) m, P = 0.032) .Conclusion In vitro chemosensitivity test based on MTT assay may be used to screen out the chemotherapy drugs in individualized chemotherapy for HCC and provide guidance for regional chemotherapy via the hepatic artery and portal vein, so as to improve the effect of chemotherapy.
- carcinoma,
- hepatocellular,
- drug screening assays

FullText(HTML)

References(10)

References

[1]YAN F.Clinical efficacy of double-intervention treatment of ad-vanced liver cancer[J].J Clin Exp Med, 2011, 10 (16) :1282-1283. (in Chinese) 严峰, 双介入治疗中晚期肝癌的临床效果观察[J].临床和实验医学杂志, 2011, 10 (16) :1282-1283.

[2]LI HP, TAO JS, GAO B, et al.The expression and clinical signifi-cance of resistance gene in hepatocellular carcinoma[J].J Clin Hepatol, 2011, 27 (9) :972-975. (in Chinese) 李海平, 陶建蜀, 高波, 等.肝细胞癌中耐药基因的表达及意义[J].临床肝胆病杂志, 2011, 27 (9) :972-975.

[3]UEDA H, FUKUCHI H, TANAKA C.Toxicity and efficacy of he-patic arterial infusion chemotherapy for advanced hepatocellular car-cinoma[J].Oncol Lett, 2012, 3 (2) :259-263.

[4]MAEJIMA K, TOKUNAGA A, KIYAMA T, et al.Chemosensitivity test for5-fluorouracil and5-chloro-2, 4-dihydroxypyridine pre-dicts outcome of gastric cancer patients receiving S-1postoperatively[J].Gastric Cancer, 2010, 13 (4) :231-237.

[5]WU B, ZHU JS, ZHANG Y, et al.Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer:One institu-tion's experience[J].World J Gastroenterol, 2008, 14 (19) :3064-3068.

[6]TANG DP, ZHANG CQ, TANG K, et al.Serial chemosensitivity test for liver cancer chemotherapy[J].Chin J Oncol Prev Treat, 2009, 1 (1) :18-20, 23. (in Chinese) 唐东平, 张翠卿, 唐凯, 等.系列化疗药敏或耐药试验在肝癌化疗中的应用研究[J].中国癌症防治杂志, 2009, 1 (1) :18-20, 23.

[7]SARGENT JM.The use of the MTT assay to study drug resistance in fresh tumour samples[J].Recent Results Cancer Res, 2003, 16 (1) :13-25.

[8]BURSTEIN HJ, MANGU PB, SOMERFIELD MR, et al.American So-ciety of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays[J].J Clin Oncol, 2011, 29 (24) :3328-3330.

[9]CHEN W, DENG J, YANG XJ, et al.The levels of TNF-α, sIL-2R and VEGF in patients with primary hepatic carcinoma after double intra-arterial infusion of anti-cancerous agents[J].J Clin Hepatol, 2010, 26 (2) :203-204, 209. (in Chinese) 陈卫, 邓俊, 杨小娟, 等.肝癌双灌注介入治疗后血清TNF-α、sIL-2R以及VEGF水平的变化与预后相关[J].临床肝胆病杂志, 2010, 26 (2) :203-204, 209.

[10]ZHENG JL, LIANG LJ, HU WJ, et al.Distribution of5-FU in rat plasma and liver tissue after local5-FU infusion[J].J South-ern Med Univ, 2008, 28 (5) :823-827. (in Chinese) 郑惊雷, 梁力建, 胡文杰, 等.区域性灌注化疗时5-FU的血液和肝脏组织药物浓度分布特征[J].南方医科大学学报, 2008, 28 (5) :823-827.

Relative Articles

[1]	Shi Feng, Lei YuPeng. Effect of statins on hepatocellular carcinoma in patients with type 2 diabetes[J]. Journal of Clinical Hepatology, 2019, 35(1): 161-163. doi: 10.3969/j.issn.1001-5256.2019.01.031
[2]	Zheng WeiPing, Shen ZhongYang. Risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma and related control strategies[J]. Journal of Clinical Hepatology, 2019, 35(11): 2391-2395. doi: 10.3969/j.issn.1001-5256.2019.11.003
[3]	Li Hao, Duan XuHua, Han XinWei, Ren JianZhuang, Li FengYao, Kuang DongLin, Li FangZheng. Clinical effect of transarterial chemoembolization combined with radiofrequency ablation in treatment of rabbit VX2 liver tumors[J]. Journal of Clinical Hepatology, 2018, 34(4): 779-783. doi: 10.3969/j.issn.1001-5256.2018.04.017
[4]	Fan YongQiang, Dong ShengLi. Recent advances in targeted drug therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(2): 424-428. doi: 10.3969/j.issn.1001-5256.2018.02.046
[5]	Yao ChangYu, Du YingRui, Ke Shan, Gao Jun, Sun WenBing. Current status of non-surgical local therapies for hepatocellular carcinoma originating from the caudate lobe and related research advances[J]. Journal of Clinical Hepatology, 2018, 34(1): 195-198. doi: 10.3969/j.issn.1001-5256.2018.01.043
[6]	Liu Qi, Liu Wei, Lin ZhiBin, Dou KeFeng. Biological function of translationally controlled tumor protein and its role in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(8): 1797-1800. doi: 10.3969/j.issn.1001-5256.2018.08.046
[7]	Yang GuiMin, Zhao YunSheng, Wang ChunHua, Jin Liang. Research advances in tumor markers for the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(1): 199-203. doi: 10.3969/j.issn.1001-5256.2018.01.044
[8]	Ceng QingLei, Yu ZuJiang. Whether antiviral therapy can reduce the incidence of hepatocellular carcinoma in patients with chronic HCV infection[J]. Journal of Clinical Hepatology, 2017, 33(6): 1075-1078. doi: 10.3969/j.issn.1001-5256.2017.06.011
[9]	Zhang Ying, Liu Ming, Peng XiaoHua, Sun LinLin, Wang YaoHui, Xie ShiBin. Clinical features of patients developing primary hepatocellular carcinoma during anti-HBV therapy with nucleos (t) ide analogues[J]. Journal of Clinical Hepatology, 2017, 33(4): 679-683. doi: 10.3969/j.issn.1001-5256.2017.04.016
[10]	Xu QingNian, Lu YunFei, Tang BoZong, Chen XiaoRong, Yang ZongGuo. Correlation between mRNA expression of heat shock protein in tumor tissue and tumor stage in patients with HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(5): 869-874. doi: 10.3969/j.issn.1001-5256.2017.05.015
[11]	Yu Tong, Zhai XiaoFeng, Liu Qun, Meng YongBin, Lu JianYing, Chen Zhe. Clinical effect and safety of hepatic arterial infusion of cinobufotalin injection combined with lipiodol chemoembolization in treatment of Barcelona Clinic Liver Cancer stage C primary liver cancer[J]. Journal of Clinical Hepatology, 2017, 33(2): 281-285. doi: 10.3969/j.issn.1001-5256.2017.02.015
[12]	Liang Yuan, Wang ShiMing, Shi ZhenMing. Research advances in application of molecular- targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(3): 601-604. doi: 10.3969/j.issn.1001-5256.2016.02.03.045
[13]	Zhu XiaoLi, Shen Jian. Application of local ablative therapies for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 56-61. doi: 10.3969/j.issn.1001-5256.2016.01.008
[14]	Wang Ting, Liu Mei, Dong Lei, Duan ZhongPing. Application of tumor-associated antigens and their autoantibodies in early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(7): 1418-1421. doi: 10.3969/j.issn.1001-5256.2016.07.047
[15]	Yang XiaoXiao, Ma Hong. Research advances in tumor markers of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 811-815. doi: 10.3969/j.issn.1001-5256.2016.04.047
[16]	Liu Qi, Wu ZhenMing, Qi XiuHeng, Guo Qian. Survival analysis of intrahepatic arterial infusion of Endostar combined with transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(2): 225-227. doi: 10.3969/j.issn.1001-5256.2015.02.019
[17]	Zhang YuHuan, Jian ZhiYuan, Gao Yi, Zhu YanZhi. Prognostic impact of portal vein immunochemotherapy in patients after resection of primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(11): 1186-1189. doi: 10.3969/j.issn.1001-5256.2014.11.024
[18]	Ji Ru, Dou KeFeng, Xu Hui. Prevention and management of recurrence and metastasis of hepatocellular carcinoma after liver transplantation[J]. Journal of Clinical Hepatology, 2014, 30(1): 7-10. doi: 10.3969/j.issn.1001-5256.2014.01.003
[19]	Ma DeNing, Zhu XiaoDong, Tang ZhaoYou. Role of cancer- associated fibroblasts in growth and metastasis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(9): 865-868. doi: 10.3969/j.issn.1001-5256.2014.09.007
[20]	Guan Tie, Zou QingHua. The clinical observation of continuous hyperthermic peritoneal perfusion chemotherapy with endogenetic field tumor hyperthemic system in the treatment of advanced primary hepatic carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(5): 531-532+544.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (386) PDF downloads(109)

Application of chemosensitivity test in regional chemotherapy for hepatocellular carcinoma via hepatic artery and portal vein

DOI: 10.3969/j.issn.1001-5256.2013.08.016

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Application of chemosensitivity test in regional chemotherapy for hepatocellular carcinoma via hepatic artery and portal vein

DOI: 10.3969/j.issn.1001-5256.2013.08.016

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content